Save time and jump to the most important pieces.
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
15-12G - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
10-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
BOULDER, Colo., June 17, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today that it has filed an Answer (the "Answer") to a Verified Petition for Appointment of a Custodian Pursuant to 8 Del. C. § 226 (the "Delaware Petition") that was filed with the Court of Chancery of the State of Delaware (the "Court") on May 17, 2024 by a stockholder and former General Counsel, Chief Compliance Officer, and Secretary of the Company, David R. McAvoy (the "Petitioner"). The Delaware Petition, to which the Answer outlines the Company is in overall agreement with, specifically requests that the Court issue an order appointing Albert N. Ma
Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024 BOULDER, Colo., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") would like to remind its stockholders to vote their proxy ahead of the Company's upcoming special meeting of stockholders on February 15, 2024 (the "Special Meeting") at 12:00 p.m. Eastern Time to seek stockholder approval of the liquidation and dissolution of the Company (the "Dissolution") and the plan of liquidation and dissolution (the "Plan of Dissolution"). All stockholders of record of the Company's outstanding shares of
New record date expected to be January 11, 2024 Company intends to seek judicial dissolution if the liquidation and dissolution is not approved by Fresh Tracks' stockholders at new special meeting, which would reduce the amount of cash distributable to stockholders BOULDER, Colo., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX) ("Fresh Tracks" or the "Company") announced today plans to hold a new special meeting of stockholders on February 15, 2024 (the "Special Meeting") to seek stockholder approval of the liquidation and dissolution of the Company (the "Dissolution") and the plan of liquidation and dissolution (the "Plan of Dissolution"). As of today's r
BOULDER, Colo., June 17, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today that it has filed an Answer (the "Answer") to a Verified Petition for Appointment of a Custodian Pursuant to 8 Del. C. § 226 (the "Delaware Petition") that was filed with the Court of Chancery of the State of Delaware (the "Court") on May 17, 2024 by a stockholder and former General Counsel, Chief Compliance Officer, and Secretary of the Company, David R. McAvoy (the "Petitioner"). The Delaware Petition, to which the Answer outlines the Company is in overall agreement with, specifically requests that the Court issue an order appointing Albert N. Ma
BOULDER, Colo., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. ("Fresh Tracks" or the "Company") (NASDAQ:FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced its Board of Directors has appointed Andrew Sklawer, the Company's current President, as Chief Executive Officer (CEO), effective February 1, 2023. Mr. Sklawer will succeed Rob Brown, who has led the company as CEO since 2019 and is retiring. Mr. Brown will continue to serve as a non-executive member of the Board
The Dow Jones index closed higher by around 575 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Grove Collaborative Holdings The Trade: Grove Collaborative Holdings, Inc. (NYSE:GROV) President and CEO Jeffrey Michael Yurcisin bought a total of 17,100 shares at an average price of $1.63. To acquire these shares, it cost around $27,951. Wh
The Dow Jones index closed lower by 0.5% on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. MultiPlan The Trade: MultiPlan Corporation (NYSE:MPLN) Director Anthony Colaluca Jr bought a total of 160,000 shares at an average price of $0.60. To acquire these shares, it cost around $96,000. What's Happening: On May 8, MultiPlan posted a GAAP loss of
The Dow Jones index closed higher by more than 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. TSS The Trade: TSS, Inc. (OTC:TSSI) President and CEO Darryll E Dewan acquired a total of 10,000 shares an average price of $0.60. To acquire these shares, it cost around $6,000.. What’s Happening: On March 28, TSS, reported results for its
SC 13D - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)
SC 13G/A - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)
SC 13G/A - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)
Reported positive topline results from SAD and MAD parts of Phase 1 study of lead DYRK1A inhibitor FRTX-02 in March 2023 Ongoing evaluation of strategic options to further develop FRTX-02 and maximize shareholder value Strengthened balance sheet with aggregate net proceeds of $6.6 million raised under an ATM program in March 2023 BOULDER, Colo., May 10, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today
Positive topline results from single and multiple ascending dose parts of the Phase 1 study of FRTX-02 support its continued development as a potential first-in-class, once-daily oral treatment for atopic dermatitis and/or other autoimmune diseases Continuing to evaluate strategic options to further develop FRTX-02 and maximize shareholder value Raised aggregate net proceeds of $6.6 million under ATM program in March 2023 BOULDER, Colo., March 30, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription the